NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Nicotine Surges as Smoking Sags.” To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast To view the full editorial, please visit: https://nnw.fm/WNblw The fact remains that an estimated 1.1 billion people smoked cigarettes in 2019. According to stats from the World Health Organization, a stunning 780 million people...
NEW YORK, May 25, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Lexaria Bioscience Corp. (NASDAQ: LEXX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Nicotine Surges as Smoking Sags,” please visit: https://nnw.fm/WNblw Seems like yesterday people were smoking cigarettes...
25 th patent grant is Lexaria's first-ever patent for the enhanced delivery of antivirals KELOWNA, BC / ACCESSWIRE / April 21, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the Company is receiving its first-ever patent for the use of DehydraTECH technology in the enhanced delivery of antiviral drugs. Lexaria has received notification from the United States Patent and Trademark Office that patent...
HYPER-H21-4 will evaluate DehydraTECH TM -CBD for reducing blood pressure together with other potential clinical benefits This study is designed to enhance Lexaria's probabilities of success with its expected subsequent Investigational New Drug application filing KELOWNA, BC / ACCESSWIRE / April 19, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that it has begun its multi-week human...
Data From This Human Study, Together With the Findings From Lexaria's Other Previously Announced Successful Studies, Intended To Support the Company's Plans To Seek Approvals by the U.S. Food and Drug Administration KELOWNA, BC / ACCESSWIRE / April 14, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that all data analyses from its simulated pulmonary hypertension clinical study HYPER-H21-3 have been...
Lexaria's DehydraTECH-nicotine pouch performance will be compared to existing leading brands currently sold in the United States suc h as ON! and Zyn KELOWNA, BC / ACCESSWIRE / April 12, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces details of human nicotine study NIC-H22-1, which is expected to begin dosing this summer. Study NIC-H22-1 is a minimum 36-person human pharmacokinetic ("pk")...
KELOWNA, BC / ACCESSWIRE / April 11, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has entered new agreements with Altria Client Services, LLC ("Altria"). Under the terms of these agreements, Lexaria will receive a fee to provide certain DehydraTECH powder-based nicotine formulations to be evaluated by Altria. The new agreements are in effect until March 31, 2023. About Lexaria Bioscience...
Program EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity; DehydraTECH-CBD test articles have been delivered to the laboratory ready to commence dosing. KELOWNA, BC / ACCESSWIRE / March 15, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that the first phase of its epilepsy research program EPIL-A21-1 is beginning this...
Newest granted patent expands worldwide patent portfolio to 24 KELOWNA, BC / ACCESSWIRE / March 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted a new patent entitled "Compositions Infused with Nicotine Compounds and Methods of Use Thereof". The new Australian patent expands upon Lexaria's international intellectual property rights to apply DehydraTECH enhancement technology to...
DehydraTECH TM sildenafil delivered 74% more drug at 4 minutes, than the control KELOWNA, BC / ACCESSWIRE / February 2, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive findings in an animal study evaluating DehydraTECH TM processing of the phosphodiesterase inhibitor ("PDE5 inhibitor") sildenafil, for potential application in the management of erectile dysfunction. A clear trend toward...
KELOWNA, BC / ACCESSWIRE / January 27, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders. Dear Shareholders, Will anyone ever forget 2021? If a global pandemic and unprecedented weather events don't resonate, then perhaps the tectonic changes in politics or social involvement in investing epitomized...
"Cannabinoids have the potential to prevent as well as treat infection by SARS-CoV-2 " KELOWNA, BC / ACCESSWIRE / January 18, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, comments on an independent January 10 study, available here , that discovered that "Cannabinoids Block Cellular Entry of SARS-CoV-2 and the Emerging Variants". In an interview granted to vice.com, lead research scientist Dr. Richard van...
• Dosing is expected to begin by April, 2022 KELOWNA, BC / ACCESSWIRE / December 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms, is pleased to report that Independent Review Board ("IRB") approval has been received ahead of schedule for its upcoming DehydraTECH-CBD human hypertension study HYPER-H21-4. This study should "de-risk" outcomes prior to Lexaria's planned entry into regulatory pathways...
KELOWNA, BC / ACCESSWIRE / December 16, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the " Company " or " Lexaria "), a global innovator in drug delivery platforms announces that it has entered into an advertising and media agreement (the " Contract ") for media buys and digital marketing with SRAX, Inc. (" SRAX "). "Lexaria is pleased to be working with SRAX to inform and engage a broad investor community in this significant, year-long media outreach campaign," said Chris Bunka,...
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human clinical study HYPER-H21-3 is expected to complete all dosing and sample collection this week. Formal hospital and ethics board approvals for human clinical study HYPER-H21-3 had been received in March. Study HYPER-H21-3 used a placebo-controlled and blinded design, with administration of a single...
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to issue follow-up results from human clinical study HYPER-H21-2 confirming that DehydraTECH TM -processed cannabidiol ("CBD") reduces arterial stiffness, potentially broadening its application to treatment of cardiovascular and other...
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for several new and ongoing DehydraTECH TM applied R&D programs for 2022. The studies mentioned herein are only a fraction of Lexaria's 2022 work programs. "Calendar 2022 will continue to see significant milestones in utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and...
DehydraTECH-CBD also being evaluated in three other human clinical studies Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces a significant new study to expand its hypertension clinical program and provides updates on three ongoing human clinical studies evaluating its proprietary DehydraTECH-CBD...
New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECH TM -CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, has commenced an important new study exploring whether DehydraTECH TM -CBD evidences superior ability to inhibit seizure activity compared to both generic cannabidiol ("CBD") and Epidiolex....
DehydraTECH delivers equivalent quantity of oral THC three times faster: 15 minutes vs. 45 minutes KELOWNA, BC / ACCESSWIRE / October 13, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that its recent oral tetrahydrocannabinol ("THC") absorption study THC-A21-1 revealed that DehydraTECH TM -THC delivered via oral ingestion required only 15 minutes to deliver THC levels in blood plasma...